GMAB News and Press, Genmab A/S From 03/12/22

Seagen had achieved net product sales of $1.4 billion in 2021, which was an annual growth rate of 38%. TIVDAK was approved in September of 2021 for recurrent or metastatic cervical cancer, potential to expand use of the drug for squamous cell carcinoma of the head and neck. PADCEV...

Danish biotech, Genmab (NASDAQ:GMAB) announced on Tuesday that the U.S. Food and Drug Administration (FDA) granted the orphan-drug designation to Epcoritamab for the treatment of follicular lymphoma (FL). An IgG1-bispecific antibody, Epcoritamab, is being co-developed by Genmab (GMAB) with U....

Genmab A/S (Nasdaq: GMAB) announced today that the U.S. Food and Drug Administration (FDA) has granted orphan-drug designation to the investigational medicine, epcoritamab (DuoBody®-CD3xCD20), for the treatment of follicular lymphoma (FL). Epcoritamab is being co-de...

Data from the innovaTV 207 global phase 2 trial to be presented at the American Society for Radiation Oncology (ASTRO) 2022 Multidisciplinary Head and Neck Cancers Symposium Seagen Inc. (Nasdaq: SGEN) and Genmab A/S (Nasdaq: GMAB) will present preliminary data from t...

Data from the innovaTV 207 global phase 2 trial to be presented at the American Society for Radiation Oncology (ASTRO) 2022 Multidisciplinary Head and Neck Cancers Symposium Genmab A/S (Nasdaq: GMAB) and Seagen Inc. (Nasdaq: SGEN) will present preliminary data from t...

The following slide deck was published by Genmab A/S in conjunction with their 2021 Q4 earnings call. For further details see: Genmab A/S 2021 Q4 - Results - Earnings Call Presentation

Image source: The Motley Fool. Genmab A/S (NASDAQ: GMAB) Q4 2021 Earnings Call Feb 16, 2022 , 12:00 p.m. ET Operator Continue reading For further details see: Genmab A/S (GMAB) Q4 2021 Earnings Call Transcript

Genmab A/S (GMAB) Q4 2021 Earnings Conference Call February 16, 2022, 12:00 PM ET Company Participants Jan van de Winkel – President and Chief Executive Officer Anthony Pagano – Chief Financial Officer Anthony Mancini – Chief Operation Officer Tahi Ahmadi – Chief M...

The subsector with the best value and quality scores is pharmaceutical/biotechnology. Life science tools and healthcare equipment are the most overvalued. Fast facts on IDNA. A list of cheap stocks. For further details see: IDNA: Healthcare Dashboard For February

Genmab (NASDAQ:GMAB) is scheduled to announce FY earnings results on Wednesday, Feb. 16, before market open. The consensus EPS estimate is $6.50 and the consensus revenue estimate is $1.28B. Over the last 3 months, EPS estimates have seen 2 upward revisions and 2 downward. Revenue estimates h...